Guardant Health's Stock Declines Despite Positive Developments
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Should l Buy GH?
Source: Barron's
Guardant Health Inc's stock has dropped 9.15% and hit a 20-day low amid a broader market decline, with the Nasdaq-100 down 2.33% and the S&P 500 down 0.93%.
Despite the stock's decline, recent news highlights significant positive developments for Guardant Health. The company achieved positive free cash flow in Q3 2025, ahead of its goal, and signed a multi-year collaboration with Merck to develop companion diagnostics. Additionally, Guardant360 CDx received FDA approval as a companion diagnostic for Pfizer's Braftovi and Eli Lilly's Erbitux, enhancing its competitive position in the oncology market. Investors remain optimistic about the company's future, although caution is advised.
The implications of these developments suggest that while the stock is currently under pressure, the positive financial performance and strategic collaborations could lead to a rebound in investor confidence and stock price appreciation in the long term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 90.490
Low
105.00
Averages
124.69
High
155.00
Current: 90.490
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
U.S. Stocks Rise Following Landmark Supreme Court Ruling
- Supreme Court Ruling Impact: The U.S. Supreme Court's 6-3 decision invalidates significant portions of Trump's tariff agenda, ruling that the executive branch lacks the authority to impose such levies unilaterally, which may reshape future trade policies and boost market confidence in economic recovery.
- Weak Economic Data: U.S. Q4 GDP growth was only 1.4%, significantly below the expected 2.8%, indicating signs of economic slowdown, while the core PCE price index rose to 2.7%, exceeding expectations of 2.6%, which may lead the Fed to maintain interest rates in upcoming meetings.
- Corporate Earnings Performance: Over 75% of S&P 500 companies have reported earnings, with 74% exceeding market expectations, indicating resilience in corporate profitability, and Q4 earnings growth is projected to reach 8.4%, providing support for the stock market.
- Market Volatility and Investor Sentiment: Despite the overall rise in U.S. stocks, investor sentiment remains cautious due to geopolitical risks and mixed economic signals, with the market pricing in only a 6% chance of a rate cut at the next Fed meeting.
See More
Guardant Health Acquires MetaSight Diagnostics for $59M
- Acquisition Overview: Guardant Health has acquired Israeli startup MetaSight Diagnostics for an upfront payment of $59 million, with potential milestone payments of up to $90 million, indicating the company's strategic intent to expand in the early cancer detection sector.
- Technological Innovation: MetaSight specializes in developing early detection tests for cancer and liver fibrosis using liquid biopsy technology, and through this acquisition, Guardant aims to enhance its technological capabilities in precision medicine, thereby solidifying its market position.
- Team Retention Strategy: Guardant has opted to retain MetaSight's team in Rehovot, which not only aids in maintaining technological continuity but also fosters collaborative synergies in research and development, facilitating the rapid market introduction of new products.
- Future Growth Expectations: Guardant Health anticipates revenue growth of 27% to 30% in 2026, and this acquisition will support its expansion of the Shield and oncology product portfolio, further enhancing the company's competitiveness in the rapidly evolving cancer detection market.
See More
GUARDANT HEALTH INC: STIFEL INCREASES TARGET PRICE FROM $120 TO $130
- Stifel Raises Price Target: Stifel has increased its price target for a specific stock from $120 to $130.
- Market Implications: This adjustment reflects Stifel's positive outlook on the stock's performance in the market.
See More
Stock Market Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and Others
- Market Outlook: Stock futures are indicating potential gains on Friday.
- Investor Sentiment: Investors are overlooking rising oil prices.
- Focus on Inflation: Attention is shifting towards upcoming key inflation data.
- Economic Indicators: The market's reaction suggests optimism despite external pressures.
See More
Guardant Health Reports Strong Q4 2025 Earnings with Significant Growth
- Significant Revenue Growth: Guardant Health reported $281.3 million in revenue for Q4 2025, reflecting a 39% year-over-year increase, with full-year revenue reaching $982 million, a 33% growth, indicating strong performance and sustained demand in the oncology sector.
- Success of Shield Product: Shield generated $35 million in revenue in Q4 from approximately 38,000 tests, a substantial increase from 24,000 tests in Q3, marking it as the most successful diagnostic launch in history outside of COVID testing, positioning it as a key growth driver for the future.
- Improved Gross Margins: The non-GAAP gross margin improved to 66% in Q4, driven by reduced costs for Reveal tests and enhanced margins for Shield, with Shield's cost per test declining to approximately $450 by year-end, thereby strengthening the company's profitability.
- Optimistic 2026 Outlook: The company forecasts revenue between $1.25 billion and $1.28 billion for 2026, representing a growth rate of 27% to 30%, with oncology revenue expected to grow by 25% to 27%, reflecting management's confidence in future growth and market potential.
See More
Following Grail's Study Setback, What Remains for Cancer Blood Screening?
- Stock Performance: Grail's stock experienced a significant decline, losing half of its value last Friday.
- Market Reaction: The drastic drop in stock price indicates a negative market reaction, potentially affecting investor confidence.
See More
U.S. Stocks Rise Following Landmark Supreme Court Ruling
- Supreme Court Ruling Impact: The U.S. Supreme Court's 6-3 decision invalidates significant portions of Trump's tariff agenda, ruling that the executive branch lacks the authority to impose such levies unilaterally, which may reshape future trade policies and boost market confidence in economic recovery.
- Weak Economic Data: U.S. Q4 GDP growth was only 1.4%, significantly below the expected 2.8%, indicating signs of economic slowdown, while the core PCE price index rose to 2.7%, exceeding expectations of 2.6%, which may lead the Fed to maintain interest rates in upcoming meetings.
- Corporate Earnings Performance: Over 75% of S&P 500 companies have reported earnings, with 74% exceeding market expectations, indicating resilience in corporate profitability, and Q4 earnings growth is projected to reach 8.4%, providing support for the stock market.
- Market Volatility and Investor Sentiment: Despite the overall rise in U.S. stocks, investor sentiment remains cautious due to geopolitical risks and mixed economic signals, with the market pricing in only a 6% chance of a rate cut at the next Fed meeting.
See More
Guardant Health Acquires MetaSight Diagnostics for $59M
- Acquisition Overview: Guardant Health has acquired Israeli startup MetaSight Diagnostics for an upfront payment of $59 million, with potential milestone payments of up to $90 million, indicating the company's strategic intent to expand in the early cancer detection sector.
- Technological Innovation: MetaSight specializes in developing early detection tests for cancer and liver fibrosis using liquid biopsy technology, and through this acquisition, Guardant aims to enhance its technological capabilities in precision medicine, thereby solidifying its market position.
- Team Retention Strategy: Guardant has opted to retain MetaSight's team in Rehovot, which not only aids in maintaining technological continuity but also fosters collaborative synergies in research and development, facilitating the rapid market introduction of new products.
- Future Growth Expectations: Guardant Health anticipates revenue growth of 27% to 30% in 2026, and this acquisition will support its expansion of the Shield and oncology product portfolio, further enhancing the company's competitiveness in the rapidly evolving cancer detection market.
See More
GUARDANT HEALTH INC: STIFEL INCREASES TARGET PRICE FROM $120 TO $130
- Stifel Raises Price Target: Stifel has increased its price target for a specific stock from $120 to $130.
- Market Implications: This adjustment reflects Stifel's positive outlook on the stock's performance in the market.
See More
Stock Market Movers: Opendoor, Nvidia, Grail, Newmont, AppLovin, and Others
- Market Outlook: Stock futures are indicating potential gains on Friday.
- Investor Sentiment: Investors are overlooking rising oil prices.
- Focus on Inflation: Attention is shifting towards upcoming key inflation data.
- Economic Indicators: The market's reaction suggests optimism despite external pressures.
See More
Guardant Health Reports Strong Q4 2025 Earnings with Significant Growth
- Significant Revenue Growth: Guardant Health reported $281.3 million in revenue for Q4 2025, reflecting a 39% year-over-year increase, with full-year revenue reaching $982 million, a 33% growth, indicating strong performance and sustained demand in the oncology sector.
- Success of Shield Product: Shield generated $35 million in revenue in Q4 from approximately 38,000 tests, a substantial increase from 24,000 tests in Q3, marking it as the most successful diagnostic launch in history outside of COVID testing, positioning it as a key growth driver for the future.
- Improved Gross Margins: The non-GAAP gross margin improved to 66% in Q4, driven by reduced costs for Reveal tests and enhanced margins for Shield, with Shield's cost per test declining to approximately $450 by year-end, thereby strengthening the company's profitability.
- Optimistic 2026 Outlook: The company forecasts revenue between $1.25 billion and $1.28 billion for 2026, representing a growth rate of 27% to 30%, with oncology revenue expected to grow by 25% to 27%, reflecting management's confidence in future growth and market potential.
See More
